Regencell Bioscience (NASDAQ:RGC) Shares Up 5.5% – Time to Buy?

Regencell Bioscience Holdings Limited (NASDAQ:RGC) was up 5.5% during trading on Wednesday . The stock traded as high as $6.75 and last traded at $6.2780. 160,941 shares were traded during mid-day trading, a decline of 48% from the average session volume of 312,093 shares. The stock had previously closed at $5.95.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Regencell Bioscience has an average rating of “Sell”.

Regencell Bioscience Stock Performance

The firm’s 50-day moving average price is $20.01 and its 200 day moving average price is $25.09.

Regencell Bioscience (NASDAQ:RGC) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.00) earnings per share for the quarter.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Seven Fleet Capital Management LP acquired a new stake in shares of Regencell Bioscience during the fourth quarter worth $92,000. Amundi acquired a new position in Regencell Bioscience in the first quarter valued at about $219,000. Vident Advisory LLC boosted its holdings in Regencell Bioscience by 65.7% during the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock worth $629,000 after buying an additional 11,866 shares during the last quarter. Hudson Bay Capital Management LP bought a new position in Regencell Bioscience during the fourth quarter worth about $275,000. Finally, Bank of America Corp DE grew its position in shares of Regencell Bioscience by 59,113.8% during the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock worth $437,000 after buying an additional 17,143 shares during the period. Institutional investors and hedge funds own 0.13% of the company’s stock.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.